Logo

Takeda's Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer

Share this

Takeda's Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer

Shots:

  • The P-III PANTHER trial evaluates pevonedistat + azacitidine vs azacitidine alone in patients with higher-risk MDS- CMML and AML
  • The study did not achieve its pre-defined 1EPs of EFS- the safety profile was consistent with previously reported data of the combination regimen
  • Pevonedistat is an NAE inhibitor that leads to cancer cell death by disrupting protein homeostasis. Additionally- the results will be submitted for presentation at an upcoming medical congress

Ref: Takeda | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions